Mirum Pharmaceuticals is a biopharmaceutical company focused on rare liver diseases and related cholestatic conditions. Its marketed therapies include treatments such as Livmarli (maralixibat) for cholestatic pruritus in genetic liver disorders like Alagille syndrome. The company targets small patient populations with high unmet need through specialty hepatology products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 127.8 | — | -5.9 | — |
| Q3 2025 | 133 | — | 2.9 | — |
| Q4 2025 | 148.9 | — | -5.7 | — |
| Q1 2026 | 159.9 | — | -790.1 | — |
| Q2 2026 | 176.2 | 37.9% | -67.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Hancock Whitney Corporation (HWC), RadNet, Inc. (RDNT), Dianthus Therapeutics, Inc. (DNTH), Casella Waste Systems, Inc. (CWST), VSE Corporation (VSEC), Xenon Pharmaceuticals Inc. (XENE)